# The cytotoxic effects of glycyrrhizic acid-modified chitosan/selenium nanocomposite on osteosarcoma cancer cell line

**Authors:** Gamal El-ghannam, Souad A. Elfeky, Mahmoud T. Abo-Elfadl, Mostafa Zedan, Mahmoud Moawad

PMC · DOI: 10.1038/s41598-026-41099-w · 2026-03-20

## TL;DR

A new nanocomposite made of chitosan, selenium, and glycyrrhizic acid effectively kills osteosarcoma cancer cells while sparing healthy cells.

## Contribution

A novel glycyrrhizic acid-modified chitosan/selenium nanocomposite with selective cytotoxicity and apoptotic induction in osteosarcoma cells.

## Key findings

- GA-Cs/Se NC showed an IC50 of 76.65 ± 3.5 µg/ml against MG-63 osteosarcoma cells.
- GA-Cs/Se NC upregulated Bax and p53 while downregulating Bcl-2, indicating apoptosis.
- The NC induces ROS-mediated apoptosis with minimal inflammation and necrosis.

## Abstract

This study focuses on the preparation, characterization, and application of glycyrrhizic acid (GA)-modified chitosan/selenium (Cs/Se) nanocomposites (NC) for treating osteosarcoma cancer cells. The Cs-stabilized Se nanoparticles (Cs/Se NPs) were synthesized through a chemical reduction method, where GA was added via a surface modification technique to enhance biocompatibility and targeting efficiency. Characterization of the GA-Cs/Se NC and Cs/Se NPs was performed using various techniques, including transmission electron microscopy (TEM), X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), and Zeta potential analysis. These analyses confirmed the successful formation of spherical NPs with a uniform size (100–200 nm) and good distribution with appropriate surface modifications. GA-Cs/Se NC exhibited potent cytotoxicity against MG-63 osteosarcoma cells, with an IC50 of 76.65 ± 3.5 µg/ml, whereas it had negligible effects on bone marrow stromal cells, confirming selective tumor targeting. Additionally, gene expression analysis revealed an 8.07-fold upregulation of the pro-apoptotic Bax and a 0.36-fold downregulation of the anti-apoptotic Bcl-2, indicating mitochondrial-mediated apoptosis. Moreover, qRT-PCR revealed a 7.13-fold increase in p53 expression, corroborating the induction of DNA damage-induced apoptotic pathways. The novel GA-Cs/Se NC developed in this study uniquely integrates the ROS-mediated pro-apoptotic activity of Se NPs with the inhibitory and anti-inflammatory properties of GA, all within a Cs NPs matrix that improves stability, biocompatibility, and cellular uptake. This multifunctional design enables a synergistic mechanism combining oxidative stress induction with transcriptional modulation to selectively target and kill osteosarcoma cells while minimizing necrosis and inflammation.

## Linked entities

- **Genes:** BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], TP53 (tumor protein p53) [NCBI Gene 7157]
- **Chemicals:** glycyrrhizic acid (PubChem CID 14982), chitosan (PubChem CID 129662530), selenium (PubChem CID 6326970)
- **Diseases:** osteosarcoma (MONDO:0002623)

## Full-text entities

- **Genes:** CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, FASTK (Fas activated serine/threonine kinase) [NCBI Gene 10922] {aka FAST}, CCNL2 (cyclin L2) [NCBI Gene 81669] {aka ANIA-6B, CCNM, CCNS, HCLA-ISO, HLA-ISO, PCEE}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}
- **Diseases:** necrosis (MESH:D009336), Osteosarcoma (MESH:D012516), inflammation (MESH:D007249), cancer (MESH:D009369), Cytotoxicity (MESH:D064420), Bone marrow toxicity (MESH:D001855), gastric cancer (MESH:D013274), colorectal cancer (MESH:D015179), mitochondrial dysfunction (MESH:D028361), infection (MESH:D007239), GA (MESH:D011015), hepatic cancer (MESH:D008113), bone cancer (MESH:D001859), bacterial infection (MESH:D001424), lung cancer (MESH:D008175)
- **Chemicals:** ascorbic acid (MESH:D001205), CO2 (MESH:D002245), carbohydrate (MESH:D002241), MTT (MESH:C070243), KBr (MESH:C039004), water (MESH:D014867), copper (MESH:D003300), Se (MESH:D012643), Na2SeO3 (MESH:D018038), acridine (MESH:D000166), ROS (MESH:D017382), hydroxyl (MESH:D017665), DMSO (MESH:D004121), chitosan (MESH:D048271), paraformaldehyde (MESH:C003043), SDS (MESH:D012967), Formazan (MESH:D005562), DAPI (MESH:C007293), alcohols (MESH:D000438), CS (MESH:D002586), Acridine orange (MESH:D000165), ethylenediaminetetraacetic acid (MESH:D004492), amphotericin B (MESH:D000666), glycerol (MESH:D005990), polysaccharide (MESH:D011134), GA (MESH:D019695), hydrogen (MESH:D006859), streptomycin (MESH:D013307), ethers (MESH:D004987), polymer (MESH:D011108), GA-Cs (-), ethidium bromide (MESH:D004996), BFP (MESH:C041630), C (MESH:D002244), SYBR Green (MESH:C098022), L-glutamine (MESH:D005973), penicillin G (MESH:D010400)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** MG-63 — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0426)

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13009379/full.md

---
Source: https://tomesphere.com/paper/PMC13009379